Kymriah (tisagenlecleucel)

pCPA File Number: 22470
Negotiation Status:
Under consideration for negotiation
Indication(s):
Indicated for the treatment of adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PG0306-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable